Oregon Pharmacist Prescribing: Combined Hormonal Contraceptive With Migraine With Aura
A 24-year-old woman with no primary care clinician walks into an Oregon community pharmacy and asks the pharmacist to prescribe a 12-month supply of norgestimate/ethinyl estradiol 0.25/35 mg. Oregon allows pharmacists to prescribe self-administered hormonal contraceptives, and the pharmacist has completed the required training. The patient reports migraine with aura two to three times monthly, smokes about 10 cigarettes daily, and has a blood pressure of 138/86 mmHg; BMI is 31. She is not pregnant and has no STI symptoms. Her last cervical cancer screening was four years ago. A technician says, 'Oregon lets pharmacists prescribe birth control, so can we just fill it?' The pharmacy has a private counseling room and a self-screening form. The patient says she wants 'the same pill my friend takes' and does not want a referral because she cannot afford an office visit.
1. Does Oregon law permit the pharmacist to prescribe and dispense the requested combined hormonal contraceptive for this patient? Explain the legal authority and the screening obligation.
Read the worked answer
Oregon law permits pharmacists to prescribe and dispense self-administered hormonal contraceptives, but that authority is conditional and protocol-based. The pharmacist must complete Board-approved training, use a self-screening tool, measure blood pressure, screen for contraindications, counsel the patient, document the encounter, and refer when the product is unsafe. The legal authority is not a command to fill every request. Here, migraine with aura is a CDC Medical Eligibility Criteria category 4 condition for combined hormonal contraceptives because of increased ischemic stroke risk; the patient's smoking and elevated blood pressure add concern. The pharmacist should not prescribe the requested combined product. The technician's question reflects a common error: scope of authority is not the same as clinical appropriateness. Declining the combined product is consistent with the pharmacist's legal and professional duty, and the refusal should be documented with the reason and the alternatives offered.
2. The patient insists on the combined pill and says she will just get it from a friend. What should the pharmacist do, and what should be documented?
Read the worked answer
The pharmacist should explain in plain language why the combined pill is not recommended: migraine with aura plus smoking increases stroke risk, and the pharmacist cannot prescribe a product that fails the required screening. The pharmacist should offer a progestin-only pill, which is generally a safer option for migraine with aura and smoking, or refer to a clinic that can provide same-day contraception, including low- or no-cost options. The pharmacist should not simply tell the patient to obtain medication from a friend; that is unsafe and bypasses the screening and counseling that Oregon law requires. Documentation should include the self-screening results, blood pressure, migraine history, smoking status, the products considered and declined, the counseling provided, the referral made, and the patient's decision. If the patient leaves without a prescription, the pharmacist should document that too. The encounter should remain confidential, and the pharmacist should not disclose information to family members without authorization.
3. What must the pharmacist do if the patient agrees to a progestin-only pill instead?
Read the worked answer
The pharmacist should complete the same Oregon-required process used for any hormonal contraceptive: confirm the patient is not pregnant, measure blood pressure, review the self-screening form, assess for contraindications, select an appropriate progestin-only product, and provide counseling. Counseling should cover correct daily timing, what to do about late or missed pills, backup contraception, expected bleeding changes, and warning signs such as leg pain, chest pain, or sudden severe headache. The pharmacist should document the product, directions, quantity, counseling, and follow-up plan, and should encourage the patient to establish primary care and complete cervical cancer screening. Oregon law also requires the pharmacist to refer the patient if screening reveals a condition needing medical evaluation. The pharmacist should not prescribe a 12-month supply without a plan for follow-up, and should explain that the patient can return for blood pressure checks or new symptoms. If the patient later develops new aura symptoms or other contraindications, the pharmacist must reassess and refer.